The latest price target for Sarepta Therapeutics (NASDAQ:SRPT) was reported by Piper Sandler on July 9, 2026. The analyst firm set a price target for $20.00 expecting SRPT to rise to within 12 months (a possible 11.17% upside). 68 analyst firms have reported ratings in the last year.

The latest analyst rating for Sarepta Therapeutics (NASDAQ:SRPT) was provided by Piper Sandler, and Sarepta Therapeutics maintained their neutral rating.

The last upgrade for Sarepta Therapeutics Inc happened on July 9, 2026 when Wolfe Research raised their price target to $27. Wolfe Research previously had a peer perform for Sarepta Therapeutics Inc.

The last downgrade for Sarepta Therapeutics Inc happened on July 27, 2025 when Barclays changed their price target from $18 to $10 for Sarepta Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sarepta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sarepta Therapeutics was filed on July 9, 2026 so you should expect the next rating to be made available sometime around July 9, 2027.

While ratings are subjective and will change, the latest Sarepta Therapeutics (SRPT) rating was a maintained with a price target of $23.00 to $20.00. The current price Sarepta Therapeutics (SRPT) is trading at is $17.99, which is out of the analyst’s predicted range.